GlassScriptPhysician profile
Jacob W Charny
NPI 1336671429
$7,215.61
in general payments reported to CMS, 2019-2025
28 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $243 · 2021: $149 · 2022: $38.09 · 2023: $1,114 · 2024: $2,275 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,425 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,424.51 |
| Education | $184.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,516.50 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $781.65 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $567.97 | 2022-2025 | |
| Lilly USA, LLC | $515.25 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $498.01 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $491.91 | 2021-2025 | Adbry |
| Incyte Corporation | $415.04 | 2023-2025 | Opzelura |
| Genzyme Corporation | $392.38 | 2019-2025 | |
| Celgene Corporation | $282.74 | 2019 | |
| Amgen INC. | $262.04 | 2020-2025 | Otezla, Otezla |
| Organon LLC | $245.32 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $224.37 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $215.53 | 2019-2025 | Libtayo |
| Pfizer INC. | $210.52 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $168.64 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $111.40 | 2023-2025 | Ilumya, Blu-U, Odomzo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.90 | 2024-2025 | Cabtreo |
| Botanix Sb INC | $50.91 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $35.28 | 2024 | Vtama |
| Journey Medical Corporation | $29.64 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $26.17 | 2024 | |
| Verrica Pharmaceuticals INC. | $20.71 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $20.66 | 2024 | Xtrac |
| Biofrontera INC. | $18.04 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Blueprint Medicines Corporation | $16.89 | 2023 | Ayvakit |
| Merz North America, INC. | $15.32 | 2019 | |
| Almirall LLC | $14.47 | 2025 | Seysara |
| Paratek Pharmaceuticals, INC. | $14.35 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Charny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.